Abstract: A method is described for using IL-12R?1/IL-23R, CCR6, BATF, AHR, STAT3, IRF4 crucial actors in TH17 cells differentiation as markers for acne. Also described are methods of their use to diagnose acne, and to screen inhibitors of Th17 differentiation. In particular, methods are described for inhibiting IL12R?1/1L-23R, CCR6, BATF, AHR, STAT3, IRF4 and the use of these screened inhibitors in acne treatment.

Abstract: A method is described for using ROR gamma t or ROR alpha to diagnose acne and/or to screen inhibitors of Th17 differentiation. Specifically described, are methods of inhibiting ROR gamma t or ROR alpha and use of the screened inhibitors in acne treatment.

Abstract: Described herein is a method of using a topical, pharmaceutical composition, particularly a dermatological composition, comprising naratriptan to treat rosacea and in particular erythematotelangiectatic rosacea.

Abstract: Described herein is a method of using a topical, pharmaceutical composition, particularly a dermatological composition, comprising naratriptan to treat rosacea and in particular erythematotelangiectatic rosacea.

Abstract: The invention relates to the identification of the ovo-like zinc finger 1 (OVOL1) as a new biomarker of moderate to severe acne. The invention also relates to products and methods for detecting, diagnosing, staging, treating or monitoring the course of acne in a human subject.

Abstract: A method is described for using IL-12R?1/IL-23R, CCR6, BATF, AHR, STAT3, IRF4 crucial actors in Th17 cells differentiation as markers for acne. Also described are methods of their use to diagnose acne, and to screen inhibitors of Th17 differentiation. In particular, methods are described for inhibiting IL12R?1/IL-23R, CCR6, BATF, AHR, STAT3, IRF4 and the use of these screened inhibitors in acne treatment.

Abstract: The invention relates to the identification of Adaptor-Related Protein Complex 5, subunit 1 (AP5B1) as a biomarker of moderate to severe acne. The invention also relates to products and methods for detecting, diagnosing, staging, treating or monitoring the course of acne in a human subject.

Abstract: A method is described for using ROR gamma t or ROR alpha to diagnose acne and/or to screen inhibitors of Th17 differentiation. Specifically described, are methods of inhibiting ROR gamma t or ROR alpha and use of the screened inhibitors in acne treatment.

Abstract: The present invention relates to novel melanocortin receptor antagonist compounds corresponding to the general formula (I) below: to compositions containing them, to the process for preparing them and to their use in pharmaceutical or cosmetic compositions.

Abstract: Melanocortin receptor antagonist compounds, processes for preparing them and uses thereof in human medicine and cosmetics are described. Melanocortin receptor antagonist compounds corresponding to the general formula (I): compositions containing them, and processes for their preparation and their use in pharmaceutical or cosmetic compositions are also described.

Abstract: A process for the characterization of rosacea is disclosed. The process can include identifying for the first time new markers in leukocyte recruitment as well as the therapeutic applications targeting rosacea.

Abstract: Provided herein are novel benzenesulfonamide compounds having a structure of formula (I) below: as well as to the method for synthesizing same and to the use thereof in pharmaceutical compositions to be used in human or veterinary medicine, as well as to the use thereof. Also provided herein are methods of using the disclosed pharmaceutical compositions for the treatment of neuroinflammatory skin diseases such as acne.

Abstract: A method is described for using ROR gamma t or ROR alpha to diagnose acne and/or to screen inhibitors of Th17 differentiation. Specifically described are methods of inhibiting ROR gamma t or ROR alpha and use of the screened inhibitors in acne treatment.

Abstract: A method is described for using IL-12R 1/IL-23R, CCR6, BATF, AHR, STAT3, IRF4 crucial actors in Th17 cells differentiation as markers for acne. Also described are method of their use to diagnose acne, to screen inhibitors of Th17 differentiation. In particular, methods are described for inhibiting IL12R 1/IL-23R, CCR6, BATF, AHR, STAT3, IRF4 and the use of these screened inhibitors in acne treatment.

Abstract: Melanocortin receptor antagonist compounds, processes for preparing them and uses thereof in human medicine and cosmetics are described. Melanocortin receptor antagonist compounds corresponding to the general formula (I): compositions containing them, and processes for their preparation and their use in pharmaceutical or cosmetic compositions are also described.

Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the phosphatidylcholine transfer protein (PCTP), and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.

Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of G0/G1 switch protein 2 (GOS2), and also utilizes modulators of the expression or of the activity of this protein, for the treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea; methods for the in vitro diagnosis of or in vitro prognosis for these pathologies are also featured.

Abstract: An in vitro or in vivo method for screening for candidate compounds for the preventive or curative treatment of acne, of seborrhoeic dermatitis or of skin disorders associated with hyperseborrhoea, includes determining the ability of a compound to modulate the expression or the activity of the CYP2B15 and/or glycerol-3-phosphate dehydrogenase 1 (GPD1) proteins.

Abstract: An in vitro method of screening for candidate compounds for the preventive or curative treatment of acne entails determination of the ability of a compound to inhibit the expression or the activity of TACE, and also to the administration of inhibitors of the expression or of the activity of this enzyme, in the treatment of acne.

Abstract: An in vitro method for screening candidate compounds for the preventive or curative treatment of acne, includes the determination of the capacity of a compound to modulate the expression or the activity of UDP-glucose ceramide glucosyltransferase (UGCG), and the use of modulators of the expression or activity of this enzyme for the treatment of acne or skin disorders associated with a hyperkeratinization; methods for the in vitro diagnosis or prognosis of these pathologies are also described.